IP Update
The invention, the patent’s abstract states, “relates to a double-stranded ribonucleic acid for inhibiting the expression of a mutant gene, comprising a complementary RNA strand having a complementary region that is substantially complementary to a portion of the mutant gene, and which is partially complementary to the corresponding wild-type gene.